MO-U.S.-SOYBEAN-EXPORT
6.7.2020 16:19:08 CEST | Business Wire | Press release
A new meta-analytical study reinforces U.S. Soy’s reputation for being a global leader in quality and nutrient-density. The study, entitled, “Chemical composition, protein quality and nutritive value of commercial soybean meals produced from beans from different countries,” demonstrates that not all soybean meals are created equal and that meal from different countries of origin should be treated individually when formulating swine and poultry diets. The data from this study were then processed by the Nutrient Value Calculator (NVC), a software tool constructed by Genesis Feed Technologies, a company built to bring visibility into feed costs. This cost analysis supported the economic benefits of U.S. soybean meal relative to meal from other origins as a key ingredient in poultry rations.
Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid in Spain and study co-author, first presented findings from the meta-analysis at the U.S. Soybean Export Council’s (USSEC) Asia Trade Exchange to 850 U.S. Soy customers and soybean industry representatives. This pioneering compilation of research is the most comprehensive quality review of soybean meal that has ever been conducted, and it gives customers greater clarity around soybean meal quality from different countries of origin. The meta-analysis looked at 18 different studies and 1,944 samples to quantify the relationship between country of origin of the bean and the chemical composition and nutritive value of the soybean meal. Soybeans from the following origins were analyzed: Argentina (ARG), Brazil (BRA), USA (USA) and India (IND).
“One of the main points from the study, is that customers should be using different matrices for the evaluation of the nutritional value of soybean meals of different origins,” said Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid, Spain . “If they buy only based on protein or vegetable sucrose content, they may buy a product that is actually lower quality. Therefore, it is important to check all of the values that are related to the nutritive value of the soybean meal before making purchase decisions, which this study addresses.”
The data in this meta-analysis forms a new key pillar of the economic evaluation of soybean meal in global markets. Using the Nutrient Value Calculator from Genesis Feed Technologies , the economic value of U.S. soybean meal can be evaluated in global markets using formulas representative of the regional feed manufacturers. Nutrient values and prices of all the other components of the diet are also used in this calculation. The NVC indicates that U.S. soybean meal is the leading contributor to cost reduction in broiler diets.
“Our company was thrilled to participate in this groundbreaking research conducted by the U.S. Soybean Export Council,” said Peter Schott, CEO and Co-Founder of Genesis Feed Technologies . “We hope that buyers take note of the results, purchase more U.S. soy and see a significant reduction in their feed costs. This NVC analyzes economic nutritional value of soybean meals from different origins to give traders and buyers a platform to connect with nutritionists directly to better inform their feed investments.”
When comparing cost reductions with incorporation of data from the aforementioned meta-analytical study, premiums of U.S. soybean meal range from $14.57 to $23.24 per tonne over Argentine soybean meal and range from $2.48 to $10.26 per tonne over Brazilian soybean meal.
“U.S. soy and soybean meal products offer a price advantage and rank first on a number of important nutritional attributes when compared to other origins, including remarkable amino acid and energy profiles,” said Paul Burke, USSEC’s Senior Director for U.S. Soy Marketing . “This will continue to ensure we deliver a valuable, consistent and more economical product that our customers can count on.”
Soybean meal is an important source of protein for the global feed industry, where it is used in livestock, poultry and aquaculture diets. To meet this demand for animal feed, the farmers that grow sustainable U.S. soy not only care about being a reliable supplier but take pride in providing a high-quality product to their international customers.
“The world’s need for a high-quality protein product like U.S. soybean meal will be critical as our population continues to grow. And U.S. farmers around the country are ready and willing to meet that need,” said Monte Peterson, Chairman of USSEC , board member of the American Soybean Association and soybean farmer in Valley City, N.D. “Our soybean farmers provide a consistent, nutritious and efficient source of protein for both the food and feed sectors. This meta-analysis is important because it shows how U.S. soy is the most high-quality and best economic choice, backed by science.”
To learn more and access a summary of the meta-analysis, click here . And register to watch USSEC’s recorded webinar with Dr. Gonzalo Mateos and Genesis Feed Technologies to hear key insights about the meta-analysis and better understand the nutritional value of U.S. soybean meal as compared to different origins.
ABOUT U.S. SOYBEAN EXPORT COUNCIL
The U.S. Soybean Export Council (USSEC) is a dynamic partnership of U.S. soybean producers, processors, commodity shippers, merchandisers, allied agribusinesses and agricultural organizations working to build preference for U.S. soy throughout the world. Through a global network of international offices and strong support in the U.S., USSEC works to build a preference for U.S. soybeans and soybean products, advocates for the use of soy in feed, aquaculture and human consumption, promotes the benefits of soy use through education, and connects industry leaders through a robust membership program. USSEC is partially funded by the United Soybean Board. Learn more at www.ussec.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
